Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value

Respiratory syncytial virus (RSV) infection is the most common cause of lower respiratory tract infection and the leading cause of hospitalization among young children, incurring high annual costs among US children under the age of 5 years. Palivizumab has been found to be effective in reducing hosp...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Open Forum Infect Dis
Hlavní autoři: Olchanski, Natalia, Hansen, Ryan N, Pope, Elle, D’Cruz, Brittany, Fergie, Jaime, Goldstein, Mitchell, Krilov, Leonard R, McLaurin, Kimmie K, Nabrit-Stephens, Barbara, Oster, Gerald, Schaecher, Kenneth, Shaya, Fadia T, Neumann, Peter J, Sullivan, Sean D
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2018
Témata:
Review Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5833316/
https://ncbi.nlm.nih.gov/pubmed/29516023
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofy031
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky